Antileukotriene Agents in the Management of Asthma

  • Sheldon L. Spector
Part of the Current Clinical Practice book series (CCP)


The role of inflammation in asthma has been the main theme of various guidelines on its treatment and the emphasis of the National Asthma Education Program (NAEP). There are several treatment options when selecting anti-inflammatory agents for managing asthma patients. Although inhaled corticosteroids are associated with considerably fewer side effects than oral corticosteroids, and currently are the anti-inflammatory medication of choice, they nevertheless have certain side effects. In the usual doses, they have been shown to be safe and well tolerated. However, with higher doses, they can produce adverse effects such as oral candidiasis, dysphonia, osteoporosis, possible growth retardation and even ocular effects, such as glaucoma and cataract formation.


Allergen Challenge Beclomethasone Dipropionate Aspirin Challenge Peripheral Blood Eosinophil Count Antileukotriene Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: Bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998; 157: 1381–1389.PubMedCrossRefGoogle Scholar
  2. Grossman J, Smith LJ. Long-term safety and efficacy of zafirlukast in the treatment of asthma: Interim results of an open-label extension trial. Ann Allergy Asthma Immunol 1999; 82: 361–369.PubMedCrossRefGoogle Scholar
  3. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–1451.PubMedCrossRefGoogle Scholar
  4. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. JAllergy Clin Immunol 1996; 98: 859–871.CrossRefGoogle Scholar
  5. Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 1998; 102: 935–942.PubMedCrossRefGoogle Scholar
  6. National Asthma Education and Prevention Program. Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 1997.Google Scholar
  7. Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52: 1030–1035.PubMedCrossRefGoogle Scholar
  8. Spector SL. Leukotriene activity modulation in asthma. Drugs 1997; 54: 369–384.PubMedCrossRefGoogle Scholar
  9. Spector SL, Smith LJ, Glass M, “Accolate” Asthma Trialist Group. Effects of 6 weeks of therapy with oral doses of ICI-204,219, a leukotriene D receptor antagonist in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618–623.PubMedCrossRefGoogle Scholar
  10. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 177–183.PubMedCrossRefGoogle Scholar
  11. Virchow J, Hassall SM, Summerton L. Harris A. Improved asthma control over 6 weeks with Accolate (zafirlukast) in patients on high-dose inhaled corticosteroids. J Investig Med 1997; 45: 286A.Google Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Sheldon L. Spector

There are no affiliations available

Personalised recommendations